ToxPedia has been developed in close collaborations with several leading pharmaceutical companies, addressing their needs and requirements. In addition, Genedata’s membership in research consortia such as InnoMed PredTox, Biocop, NewGeneris, Carcinogenomics and Proligen – all focusing on biomarker identification in the field of predictive toxicology – has brought extensive knowledge to ToxPedia.

In order to support the growth of knowledge in Systems Toxicology and the capabilities of interdisciplinary teams, Genedata is determined to strengthen existing relationships and to pursue new collaborations.

Addressing complex biological and technical challenges with a secure computational environment designed for large multi-site collaborations, we want to make ToxPedia the data analysis and management platform of choice for Predictive Systems Toxicology.

“InnoMed’s researchers rely on this computational environment to support and manage their scientific activities”

Predtox Project Manager, Sanofi-Aventis R&D.

Innomed PredTox Toxicogenomics (drug development) Assess the value of combining results from ‘omics technologies together with the results from more conventional toxicology methods for more informed decision making in preclinical safety evaluation 19 partners (14 pharma companies, 3 universities, 2 SMEs ) More info about InnoMed PredTox

BioCop Toxicogenomics (environmental toxicology) Improvement in the ability to monitor cereals, meats, seafood and processed foods for many classes of chemical contaminants 33 partners (universities, 2 industrials, 10 SMEs) More info about Biocop

NewGeneris Toxicogenomics (population toxicology) Development of biomarkers of dietary exposure to genotoxic chemicals and biomarkers of precarcinogenic and immunomodulatory effects in newborns using mother-child birth cohorts and biobanks 25 partners (universities, 3 SMEs) More info about NewGeneris

INCA Mechanistic biomarkers (oncology) Understanding the role of chronic viral or bacterial infectious disease in the development of cancer 27 partners (universities, 6 SMEs) More info about INCA

Carcinogenomics Toxicogenomics (carcinogenicity, genotoxicity) Development of MOA-specific in vitro tests for carcinogenic action with target organs liver, lung, and kidney 20 partners (universities, 2 industrials, 4 SMEs) More info about Carcinogenomics

Proligen Toxicogenomics (renal regeneration after damage) Development of MOA specific molecular markers and potential therapeutic approaches 7 partners (4 universities, 3 SMEs)

To find out more about Expressionist, demos and pricing please follow the navigation menus on the right hand or contact us by using this webform.